Vibha Dhawan, Director General of TERI, says the Silver Jubilee edition will examine how AI-led biology moves from discovery to deployable healthcare and manufacturing
New Delhi, 5 February 2026: BioAsia will return for its 2026 edition at a moment when artificial intelligence, advanced biology, and manufacturing are converging to reshape global healthcare delivery. Scheduled for 17–18 February 2026, the conference will mark a quarter century of BioAsia’s role in shaping life sciences dialogue, with a sharp focus on execution, scale, and real-world impact.
The 2026 edition, themed “TechBio Unleashed: AI, Automation & the Biology Revolution”, is positioned around a central question facing the sector: how to translate AI-enabled discovery and next-generation biology into scalable medicines, diagnostics, and healthcare systems. The agenda reflects a shift from exploratory innovation to industrial and clinical deployment across the life sciences value chain.
The conference will open with inaugural addresses by A. Revanth Reddy, Chief Minister of Telangana, and D. Sridhar Babu, Minister for Information Technology, Electronics, Communications, Industries and Commerce. A dedicated Telangana Rising Vision 2047 session will outline the state’s roadmap to strengthen Hyderabad’s position as a global life sciences hub, with emphasis on AI-enabled research, advanced therapeutic modalities, and next-generation biomanufacturing.
Welcoming the media at the pre-event briefing, Vibha Dhawan, Director General of TERI, said the Silver Jubilee edition reflects BioAsia’s evolution from dialogue-driven platforms to outcome-oriented engagement. She said the focus is on examining how AI-native biology can be integrated across research, development, and manufacturing to deliver measurable health and economic outcomes.
BioAsia 2026 will feature a strong lineup of global science, AI, and industry leaders. Among them, Dr Stefan Miltenyi, Founder and President of Miltenyi Biotec, will address the translation of cell and gene therapies from research to scalable manufacturing. Dr Howard Y. Chang, Chief Scientific Officer at Amgen, will discuss how AI-powered genomics and RNA biology are reshaping target discovery and precision medicine.
Pushmeet Kohli, Vice President of Science at Google DeepMind, will share insights from the frontier of artificial intelligence, highlighting how foundational models and protein science are accelerating biological discovery. Madeleine Roach, Executive Vice President and Head of Business Operations at Sanofi, will deliver a plenary address on the company’s AI-first transformation across R&D and operations.
Other speakers include Anton Groom, Chief AI Officer at MSD; Despina Solomonidou, Global Head of Technical Research and Development at Novartis; Rashmi Kumar, Chief Information Officer at Medtronic; Eamonn Warren, Group Vice President Manufacturing at Eli Lilly; and Badhri Srinivasan, Group CEO of Unilabs. Together, they will examine how data, automation, and digital systems are being embedded across discovery, clinical development, manufacturing, and diagnostics.
Across nine sessions, BioAsia 2026 will host leaders from organisations including Amgen, Novartis, Lilly, Medtronic, Sanofi, Roche, AbbVie, AstraZeneca, Novo Nordisk, Takeda, MSD, Lonza, Miltenyi Biotec, Google DeepMind, and Thermo Fisher Scientific, alongside Indian companies such as Dr Reddy’s Laboratories, Bharat Biotech, Biocon Biologics, Zydus Lifesciences, Laurus Labs, Sai Life Sciences, Aragen, Piramal Pharma, Syngene, TCS, and Apollo Hospitals.
Key discussions will focus on scaling innovation across science and supply chains, structural headwinds and growth drivers for pharma and biotech between 2026 and 2030, readiness of advanced biologics for clinical and manufacturing scale, and AI’s role across CRDMO and biomanufacturing value chains. A CEO Conclave will bring together global industry leaders to discuss resilience, geopolitics, and growth pathways for the next decade.
Day two will spotlight the evolution of Global Capability Centres in life sciences, examining how they are transitioning from support units to strategic innovation engines. Sessions will explore AI-enabled R&D, digital transformation, and India’s role in scaling TechBio solutions from local ecosystems to global markets.
With participation from policymakers, scientists, industry leaders, investors, and technology innovators, BioAsia 2026 aims to reinforce Hyderabad’s role in global life sciences while anchoring the TechBio conversation around execution, scale, and impact.
1 Comment